Blog

Soft Reboot Wellness’ Ketamine Depression Treatment Now Available for Los Altos

Oct 31 • 2 min read

Soft Reboot Wellness’ recently updated ketamine therapy provides clients with a precisely controlled and individualized course of treatment for persistent mental health problems. The center’s premises offer a peaceful setting right in the heart of the Bay Area, equipped with the latest technology to ensure comfortable and safe infusions for all patients. Following the latest…

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023 USA

Oct 30 • 1 min read

Mind Cure Health Inc. (CSE: MCUR | OTCQB: MCURF | FRA: 6MH) today announced its financial results for the three months ended August 31, 2022. All amounts are stated in Canadian dollars unless otherwise indicated. The special committee of the Company’s board of directors is continuing to explore, review and evaluate a broad range of strategic alternatives…

Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland

Oct 30 • 3 min read

Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce it has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin, a compound found in psychedelic mushrooms, for the treatment of…

Love Pharma – Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022

Oct 30 • 3 min read

LOVE Pharma Co. (CSE:LUV | FSE:G1Q0), the Company is pleased to provide the following update on the advancement of the previously announced trial focused upon clinical applications for psilocybin assisted therapy for addiction to be conducted at Johns Hopkins. “LOVE is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with…

Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

Oct 30 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced upcoming poster presentations related to its second-generation psilocybin-like lead drug candidate, MSP-1014 at two upcoming scientific conferences. The poster presentations compare…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538